"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 7 | 7 |
| 1996 | 1 | 8 | 9 |
| 1997 | 1 | 4 | 5 |
| 1998 | 4 | 6 | 10 |
| 1999 | 3 | 6 | 9 |
| 2000 | 3 | 7 | 10 |
| 2001 | 4 | 6 | 10 |
| 2002 | 5 | 6 | 11 |
| 2003 | 3 | 5 | 8 |
| 2004 | 1 | 7 | 8 |
| 2005 | 1 | 8 | 9 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 5 | 5 |
| 2008 | 2 | 3 | 5 |
| 2009 | 4 | 3 | 7 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 11 | 11 |
| 2012 | 2 | 12 | 14 |
| 2013 | 2 | 8 | 10 |
| 2014 | 3 | 7 | 10 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 5 | 6 |
| 2017 | 1 | 5 | 6 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 3 | 4 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 4 | 5 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer. 2024 Jul 26; 24(1):901.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
-
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024 Sep 01; 120(1):111-119.
-
Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis. Cancer Med. 2023 12; 12(24):21579-21591.
-
ASO Visual Abstract: Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy-An International Survey of the HAI Consortium Research Network. Ann Surg Oncol. 2023 12; 30(13):8021-8022.
-
Hepatic Artery Infusion Chemotherapy: A Quality Framework. Ann Surg Oncol. 2024 02; 31(2):701-704.
-
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
-
DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 05 20; 41(15):2701-2705.
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.